دورية أكاديمية
أعرض في EDS

Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study.

التفاصيل البيبلوغرافية
العنوان: Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study.
المؤلفون: Jensen MB; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. maj-britt.raaby.jensen@regionh.dk., Pedersen CB; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Section for Bioinformatics, DTU Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Misiakou MA; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Talman MM; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Gibson L; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Tange UB; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kledal H; Department of Breast Examinations, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark., Vejborg I; Department of Breast Examinations, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark., Kroman N; Department of Breast Surgery, Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Nielsen FC; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Ejlertsen B; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Rossing M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
المصدر: NPJ breast cancer [NPJ Breast Cancer] 2023 May 31; Vol. 9 (1), pp. 47. Date of Electronic Publication: 2023 May 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Breast Cancer Research Foundation : Nature Publishing Group, [2015]-
مستخلص: Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.
(© 2023. The Author(s).)
References: Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Mod Pathol. 2021 Jan;34(1):77-84. (PMID: 32661297)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Sci Rep. 2021 Jan 26;11(1):2259. (PMID: 33500440)
Ann Oncol. 2021 Sep;32(9):1077-1082. (PMID: 34082017)
Ann Surg Oncol. 2017 Mar;24(3):669-675. (PMID: 27770345)
Breast Cancer Res Treat. 2021 Feb;186(1):157-165. (PMID: 33150547)
Oncologist. 2015 Apr;20(4):344-50. (PMID: 25795632)
Acta Oncol. 2018 Jan;57(1):58-66. (PMID: 29164972)
Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669)
Cancers (Basel). 2020 Jul 22;12(8):. (PMID: 32708049)
Breast Cancer Res Treat. 2019 Feb;173(3):533-543. (PMID: 30361874)
N Engl J Med. 2021 Dec 16;385(25):2336-2347. (PMID: 34914339)
Bioinformatics. 2004 Feb 12;20(3):307-15. (PMID: 14960456)
Oncogene. 2012 Mar 1;31(9):1196-206. (PMID: 21785460)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
J Clin Oncol. 2018 Jul 10;36(20):2105-2122. (PMID: 29846122)
Mol Oncol. 2018 Dec;12(12):2136-2146. (PMID: 30289602)
J Clin Oncol. 1998 Aug;16(8):2672-85. (PMID: 9704717)
JCO Precis Oncol. 2022 Apr;6:e2100463. (PMID: 35476550)
JAMA Oncol. 2021 Dec 01;7(12):1851-1855. (PMID: 34617979)
J Clin Oncol. 2005 Oct 10;23(29):7265-77. (PMID: 16145055)
J Clin Oncol. 2021 May 1;39(13):1485-1505. (PMID: 33507815)
J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204)
BMC Med. 2015 Dec 18;13:303. (PMID: 26684470)
Breast Dis. 2016 Jul 28;36(2-3):65-71. (PMID: 27662272)
Breast Cancer Res Treat. 2012 Feb;131(3):827-36. (PMID: 21472434)
N Engl J Med. 2019 Feb 14;380(7):617-628. (PMID: 30516102)
Cancer Cell. 2022 Jun 13;40(6):609-623.e6. (PMID: 35623341)
Breast Cancer Res Treat. 2016 Jan;155(2):215-22. (PMID: 26740214)
Breast Cancer Res Treat. 2007 Jun;103(2):197-208. (PMID: 17039265)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Mod Pathol. 2017 Aug;30(8):1078-1085. (PMID: 28548119)
N Engl J Med. 2019 Jun 20;380(25):2395-2405. (PMID: 31157962)
Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560)
Breast Cancer Res Treat. 2008 Mar;108(2):233-40. (PMID: 17468949)
Med Oncol. 2014 Oct;31(10):163. (PMID: 25186065)
N Engl J Med. 2017 Jun 1;376(22):2147-2159. (PMID: 28564564)
APMIS. 2012 Apr;120(4):341-7. (PMID: 22429216)
Ann Surg Oncol. 2019 Feb;26(2):366-371. (PMID: 30542840)
Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925)
Breast. 2021 Apr;56:35-41. (PMID: 33601299)
معلومات مُعتمدة: NNF21OC0072287 Novo Nordisk Fonden (Novo Nordisk Foundation)
تواريخ الأحداث: Date Created: 20230531 Latest Revision: 20230603
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10232408
DOI: 10.1038/s41523-023-00551-0
PMID: 37258527
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا